Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

FOR years, Emma Morris hid from cameras, avoided mirrors and felt like a prisoner in her own body because of her weight. But ...

Doctors suggest that anybody with a Body mass index of over 30 or greater than 27 is advised to try weight loss drugs.

Medicare covers weight loss drugs including Ozempic under specific conditions when the drug also has potential use cases beyond weight loss.

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a ...

Texas Attorney General Ken Paxton on Tuesday sued U.S. drugmaker Eli Lilly for allegedly “bribing” providers to prescribe its ...

Americans are flocking to new weight loss medications like Novo Nordisk’s Wegovy and Eli Lilly's Zepbound, which work by ...

Zepbound is approved for weight loss and management, while Mounjaro is approved for the treatment of Type 2 diabetes. — Comorbidities. Mounjaro is approved for those with Type 2 diabetes.

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.